AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00039338 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant chemotherapy
Description: Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.
Study NCT00039338 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: brachytherapy
Description: Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.
Study NCT00039338 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Description: Between 45-50 Gy, in fractions of 1.8 to 2 Gy.
Study NCT00039338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).
Study NCT00039338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).
Study NCT03660306 — intervention group
Intervention type: PROCEDURE
Intervention: opioid anesthesia
Description: opioid anesthesia means using sufentanil during surgery
Study NCT03660306 — intervention group
Intervention type: PROCEDURE
Intervention: opioid free anesthesia
Description: opioid free anesthesia means giving no opioids during surgery
Study NCT01709929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
Study NCT03288818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mechlorethamine Hydrochloride Gel
Description: Given topically
Study NCT03288818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Skin Electron Beam Radiation Therapy
Description: Undergo low dose (TSEBT) Total Skin Electron Beam Therapy
Study NCT03785327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Participants either complete active and sham tDCS sessions one week apart or an autism training program.
Study NCT03785327 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Participants either complete active and sham tDCS sessions one week apart or an autism training program.
Study NCT03785327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autism Training
Description: Autism Information Presentation developed by Dr. Grace Iarocci's Autism \& Developmental Disorders Lab at Simon Fraser University
Study NCT02198313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIX 1 XX - D3
Study NCT02198313 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00427739 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac CT
Description: 64 slice spiral computerized tomography
Study NCT04353219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: compression stocking
Description: participants will continue their training program as prepared by their coach with compression stocking
Study NCT04353219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: participants will continue their training program as prepared by their coach without compression stocking
Study NCT02425891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Description: Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Study NCT02425891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
Study NCT02425891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel was administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
Study NCT02425891 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
Study NCT03078933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care arm which includes wound care, dressings and debridement.
Study NCT03078933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Therapy 2x week 6 min. plus standard of care
Description: Active Therapy Nitric Oxide delivered topically to the wound twice a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
Study NCT03078933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Therapy 2x week 12 min. plus standard of care
Description: Active Therapy Nitric Oxide delivered topically to the wound twice a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
Study NCT03078933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Therapy 4x week 6 min. plus standard of care
Description: Active Therapy Nitric Oxide delivered topically to the wound four times a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
Study NCT03078933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitric Oxide Therapy 4x week 12 min. plus standard of care
Description: Active Therapy Nitric Oxide delivered topically to the wound four times a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
Study NCT02876497 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Define macrophages migration mode
Description: Archival tumor samples analysis and blood sample testing
Study NCT04076345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prespesin assay on PATHFAST analyser
Description: Collection of parental non-opposition by the doctor taking care of the child. Addition of an additional 500μl tube to the usual blood sampling as part of the protocol for the management of children under 3 months of age with fever. This blood test contains CRP, PCT, NFS, Hemoculture.~There is no additional venipuncture. This blood sample is taken by the nurse after parental non-opposition. Transfer of the sample to the laboratory. In the laboratory, centrifugation of the sample, taking the plasma alone which will be frozen.~Delayed assay of presepsin, in series, after thawing of samples. Collection of data and analyzes by the principal investigator in collaboration with the statistician methodologist.~The immunoassay of presepsin with PATHFAST is based on chemiluminescence.
Study NCT03844113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carnosine
Description: Each participant will be given a daily oral dose 2 g of carnosine for 6 months
Study NCT03844113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each participant will be given a daily oral dose 2 g of methycellulose powder for 6 months
Study NCT05479929 — intervention group
Intervention type: OTHER
Intervention: Canadian Triage Assessment Scale (CTAS)
Description: The CTAS incorporates work of breathing into a subjective measurement in its assessment of patients and triaged.
Study NCT01927640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine (0.3-0.6 mcg/kg) infusion.
Study NCT01927640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline infusion (10 cc)
Study NCT01927640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine
Description: Intranasal cocaine (2 mg/kg)
Study NCT01927640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal cocaine
Description: Intranasal cocaine (2 mg/kg)
Study NCT01216644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 2600 mg/m²d1 i.v. every 2 weeks
Study NCT00468845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (Lyrica)
Description: 150 mg/day double blind (divided doses)
Study NCT00468845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin (Lyrica)
Description: 300 mg/day double blind (divided doses)
Study NCT00468845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo
Description: matched placebo
Study NCT01169584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Description: Intratumoral Injection Dosage from 1 x 10\^6 pfu/kg to 3 x 10\^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
Study NCT03109691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: group 1
Study NCT00957073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rheos® system
Description: Implant procedure
Study NCT03872219 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Nature-based materials
Description: In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.
Study NCT03872219 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Nature-based materials
Description: In the intervention arm, theycontain inactive and slowly-growing environmental bacteria and other microbiota. In the placebo arm, they do not contain the microbiota.
Study NCT02864251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT03109691 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: group 2
Study NCT03109691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: in all groups
Study NCT02547493 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal polysaccharide vaccine
Description: Vaccination with PPSV on first day. NB : PPSV vaccine Pneumo23 has been replaced in September 2017 by the equivalent vaccine Pneumovax because of the stop of commercialization of Pneumo23 in France by the pharmaceutical company.
Study NCT02547493 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pneumococcal conjugate vaccine
Description: Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23/Pneumovax two months later.
Study NCT02547493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Abatacept started on frst day
Study NCT00601913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study NCT00601913 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein analysis
Study NCT00601913 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Study NCT03479892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0194-0499
Description: Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level.~Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group.
Study NCT03479892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive once weekly injections of NNC0194-0499 matched placebo.
Study NCT05503407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baseline V-RESOLVE score-guided PCI
Description: Jailed wire technique (JWT): Both main vessel (MV) and side branch (SB) are wired. The MV is stented with wire protection in SB. If suboptimal results exist, the SB would be rewired and a kissing balloon inflation (KBI) is undertaken.~Jailed balloon technique: A monorail balloon is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB.~Provisional two-stent strategy: Lesion preparation and MV stenting are consistent with JWT. Provisional SB stenting could be undertaken when suboptimal results occur after SB rewiring and a KBI is undertaken.~Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which usually stenting SB before MV stenting.
Study NCT05503407 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Angiography-guided PCI
Description: The choice of interventional strategy was left to the discretion of experienced interventionists based on the coronary angiogram.
Study NCT02255474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal D +1.50 add
Description: This is a monthly disposable contact lens commercially available from CooperVision
Study NCT02255474 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal D +2.50 add
Description: This is a monthly disposable contact lens commercially available from CooperVision
Study NCT02255474 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biofinity
Description: This is a monthly disposable spherical contact lens commercially available from CooperVision
Study NCT00601913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00601913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00601913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography
Study NCT04346784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maintaining positive working memory training
Description: Participants complete 10 sessions of maintaining positive working memory training during a two-week period. Each session consists of 15 blocks.
Study NCT04346784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: repressing negative working memory training
Description: Participants complete 10 sessions of repressing negative working memory training during a two-week period. Each session consists of 15 blocks.
Study NCT04346784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive ABMT
Description: Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes.
Study NCT02864251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT02864251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT02864251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified days
Study NCT04346784 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Positive placebo ABMT
Description: Participants complete 8 sessions of attention bias modification training (ABMT) during a two-week period. Each session consists of 218 trials, and the time to complete a training session is 12 minutes
Study NCT00601913 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Study NCT04067609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: subjects will receive a single administration of either 0.1 mg/kg of intravenous dexamethasone in 90mL of normal saline
Study NCT04067609 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mL of normal saline (placebo)
Study NCT01929161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 24 International Units
Study NCT01929161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: 24 International Units
Study NCT01929161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for oxytocin)
Description: intranasal spray manufactured to mimic oxytocin nasal spray
Study NCT01929161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for oxytocin)
Description: intranasal spray manufactured to mimic oxytocin nasal spray
Study NCT01929161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lovingkindness Meditation
Study NCT01929161 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lovingkindness Meditation
Study NCT01929161 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mindfulness Meditation
Study NCT01929161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation
Study NCT01229176 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-CRM197 vaccine
Study NCT01229176 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi Polysaccharide (PS) vaccine
Study NCT01229176 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal conjugate vaccine
Study NCT00601913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00601913 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT03897894 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child Friendly Space
Description: Child Friendly Spaces (CFS) are one of the most widely used interventions to provide Mental Health and Psychosocial Support (MHPSS) as well as provide a protective environment for children in humanitarian settings.
Study NCT04744012 — intervention group
Intervention type: PROCEDURE
Intervention: Modified Periostal Pocket Flap Technique
Description: After local anesthesia, a full thickness flap was elevated from the lingual wall and a partial thickness flap was performed in the buccal one. After that, the buccal periosteum was detached and dental implants were placed following the biological drilling protocol, getting autologous bone particles from the implant site.~Patient's blood collection was performed and the plasm obtained was poured down on a sterile container and mixed with autologous bone particles collected previously during the drilling procedure. Finally the graft was placed in the pocket prepared previously and the surgical wound was sutured in two planes.
Study NCT00123266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 2 mg/kg, IA over 75 mins
Study NCT00722202 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ERB-257
Study NCT00722202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00748709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBW 2992 (Afatinib)
Description: BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
Study NCT00739180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard care control (no exercise)
Study NCT00739180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Supervised resistance exercise using stack weight equipments.
Study NCT00739180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: Supervised aerobic exercise using treadmills, bikes, and ellipticals
Study NCT02864251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified days
Study NCT01669018 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar plexus block using LUT technique
Description: Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.
Study NCT01669018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar plexus block using SSPS technique
Description: Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
Study NCT01247935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
Study NCT01247935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation
Description: Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
Study NCT01247935 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: Patients are monitored for pain and discomfort
Study NCT03322501 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Advice, Framed Messaging
Description: The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.